PMID- 28284707
OWN - NLM
STAT- MEDLINE
DCOM- 20180402
LR  - 20221207
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 31
IP  - 7
DP  - 2017 Jul
TI  - Efficacy and safety of dapagliflozin in patients with type 2 diabetes and 
      concomitant heart failure.
PG  - 1215-1221
LID - S1056-8727(16)30861-3 [pii]
LID - 10.1016/j.jdiacomp.2017.02.001 [doi]
AB  - AIM: We investigated the efficacy and safety of dapagliflozin, a sodium-glucose 
      cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and 
      heart failure (HF). METHODS: Data for patients randomized to dapagliflozin 10mg 
      or placebo with a history of HF were pooled from five clinical trials. HbA(1c), 
      weight and systolic blood pressure (SBP; two studies) were examined up to 52weeks 
      using longitudinal repeated-measures models. Composite cardiovascular outcomes, 
      hospitalizations for HF (HHF), and adverse events (AEs) were also assessed. 
      RESULTS: Patients (mean age 64years, T2DM duration ~14years, HbA(1c) 8.2%, ~50% 
      with New York Heart Association Class >/=II) received dapagliflozin (N=171) or 
      placebo (N=149). Dapagliflozin produced clinically meaningful placebo-adjusted 
      reductions in HbA(1c) (-0.55%; 95% confidence interval [CI]: -0.80, -0.30), 
      weight (-2.67kg; 95% CI: -3.88, -1.47), and SBP (-2.05mmHg; 95% CI: -5.68, 1.57) 
      over 52weeks. HHF was rare, but numerically lower with dapagliflozin (n=1 [0.6%]) 
      vs placebo (n=7 [4.7%]). Point estimates for hazard ratios of composite 
      cardiovascular outcomes favored dapagliflozin vs placebo, although 95% CIs 
      crossed unity. CONCLUSIONS: Dapagliflozin produced clinically meaningful 
      reductions in HbA(1c), weight, and SBP in patients with T2DM and HF, and was well 
      tolerated.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Kosiborod, Mikhail
AU  - Kosiborod M
AD  - Department of Cardiology, Saint Luke's Mid America Heart Institute and University 
      of Missouri, Kansas City, MO, USA. Electronic address: 
      mkosiborod@saint-lukes.org.
FAU - Gause-Nilsson, Ingrid
AU  - Gause-Nilsson I
AD  - AstraZeneca, Gothenburg, Molndal, Sweden.
FAU - Xu, John
AU  - Xu J
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Sonesson, Christian
AU  - Sonesson C
AD  - AstraZeneca, Gothenburg, Molndal, Sweden.
FAU - Johnsson, Eva
AU  - Johnsson E
AD  - AstraZeneca, Gothenburg, Molndal, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20170210
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Diuretics, Osmotic)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Membrane Transport Modulators)
RN  - 0 (Sodium-Glucose Transport Proteins)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
CIN - J Diabetes Complications. 2017 Jul;31(7):1075-1076. PMID: 28479154
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Benzhydryl Compounds/adverse effects/*therapeutic use
MH  - Diabetes Mellitus, Type 2/blood/complications/*drug therapy
MH  - Diabetic Cardiomyopathies/epidemiology/*prevention & control
MH  - Diuretics, Osmotic/adverse effects/*therapeutic use
MH  - Female
MH  - Glucosides/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Heart Failure/complications/epidemiology/*prevention & control
MH  - Humans
MH  - Hyperglycemia/prevention & control
MH  - Hypoglycemia/chemically induced/prevention & control
MH  - Hypoglycemic Agents/adverse effects/therapeutic use
MH  - Longitudinal Studies
MH  - Male
MH  - Membrane Transport Modulators/adverse effects/*therapeutic use
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Sodium-Glucose Transport Proteins/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - Cardiovascular safety
OT  - Dapagliflozin
OT  - Efficacy
OT  - Heart failure
OT  - Pooled analysis
OT  - Type 2 diabetes mellitus
EDAT- 2017/03/13 06:00
MHDA- 2018/04/03 06:00
CRDT- 2017/03/13 06:00
PHST- 2016/11/16 00:00 [received]
PHST- 2017/01/24 00:00 [revised]
PHST- 2017/02/07 00:00 [accepted]
PHST- 2017/03/13 06:00 [pubmed]
PHST- 2018/04/03 06:00 [medline]
PHST- 2017/03/13 06:00 [entrez]
AID - S1056-8727(16)30861-3 [pii]
AID - 10.1016/j.jdiacomp.2017.02.001 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2017 Jul;31(7):1215-1221. doi: 
      10.1016/j.jdiacomp.2017.02.001. Epub 2017 Feb 10.